Trial results show gout therapy of pegloticase, methotrexate maintained eGFR vs. placebo

AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.Twelve-month data from the MIRROR trial showed a higher response rate among patients with chronic kidney disease when pegloticase (Krystexxa, Horizon Pharmaceuticals) was

Related Keywords

Texas ,United States ,Baylor College Of Medicine ,Brad Marder ,Gina Brockenbrough ,Bymarke Neumann ,Abdul Abdellatif ,Horizon Pharmaceuticals ,National Kidney Foundation Spring Clinical Meetings ,Baylor College ,National Kidney Foundation Spring Clinical ,Healio Nephrology ,